Header Logo

Saad Usmani

Concepts (509)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Multiple Myeloma
249
2025
348
60.330
Why?
Antineoplastic Combined Chemotherapy Protocols
110
2025
444
19.550
Why?
Antibodies, Monoclonal
79
2025
866
14.600
Why?
Dexamethasone
70
2025
205
9.750
Why?
Antineoplastic Agents
36
2024
660
9.410
Why?
Hematopoietic Stem Cell Transplantation
38
2024
348
6.550
Why?
Immunotherapy, Adoptive
29
2025
96
5.780
Why?
Neoplasm Recurrence, Local
45
2025
334
5.390
Why?
Antineoplastic Agents, Immunological
15
2025
46
5.330
Why?
Antibodies, Bispecific
14
2025
31
4.870
Why?
B-Cell Maturation Antigen
18
2025
20
4.640
Why?
Bortezomib
32
2025
56
4.320
Why?
Neoplasm, Residual
19
2025
42
4.170
Why?
Humans
277
2025
62549
3.630
Why?
Thalidomide
21
2024
34
3.560
Why?
Antibodies, Monoclonal, Humanized
16
2025
233
3.080
Why?
Aged
114
2025
14212
2.860
Why?
Transplantation, Autologous
32
2024
125
2.610
Why?
Treatment Outcome
58
2025
5558
2.420
Why?
Middle Aged
103
2025
17303
2.280
Why?
Recurrence
28
2025
630
2.250
Why?
Hematologic Neoplasms
5
2025
48
2.240
Why?
Male
120
2025
29393
2.230
Why?
Female
121
2025
32404
2.110
Why?
Drug Resistance, Neoplasm
25
2024
194
2.070
Why?
Drug-Related Side Effects and Adverse Reactions
4
2023
144
2.030
Why?
Oligopeptides
15
2025
133
1.990
Why?
Aged, 80 and over
50
2025
5394
1.900
Why?
Adult
77
2025
16577
1.850
Why?
Biomarkers, Tumor
16
2025
502
1.840
Why?
Plasma Cells
8
2022
52
1.580
Why?
Prognosis
34
2025
1717
1.580
Why?
Neoplasms, Second Primary
5
2023
47
1.540
Why?
Injections, Subcutaneous
10
2022
70
1.480
Why?
Chromosome Aberrations
8
2025
68
1.400
Why?
T-Lymphocytes
8
2024
1004
1.380
Why?
Melphalan
9
2024
23
1.360
Why?
ADP-ribosyl Cyclase 1
6
2023
28
1.350
Why?
Clinical Trials as Topic
10
2023
452
1.310
Why?
Salvage Therapy
9
2023
73
1.290
Why?
Administration, Intravenous
8
2022
66
1.260
Why?
Quality of Life
9
2025
1217
1.230
Why?
Immunologic Factors
7
2022
104
1.180
Why?
Survival Rate
18
2025
838
1.100
Why?
Flow Cytometry
5
2022
669
1.090
Why?
Practice Guidelines as Topic
7
2024
725
1.070
Why?
Retrospective Studies
32
2025
6494
1.060
Why?
Cell- and Tissue-Based Therapy
6
2023
39
1.060
Why?
Myeloma Proteins
7
2021
7
1.030
Why?
Immunoglobulin Light Chains
4
2021
16
0.990
Why?
Waldenstrom Macroglobulinemia
3
2023
8
0.990
Why?
HSP90 Heat-Shock Proteins
3
2011
65
0.960
Why?
Physicians
4
2023
464
0.950
Why?
Positron-Emission Tomography
4
2015
208
0.940
Why?
Chromosomes, Human, Pair 1
4
2025
23
0.920
Why?
Membrane Glycoproteins
5
2020
669
0.890
Why?
Patient Reported Outcome Measures
5
2025
139
0.830
Why?
Smoldering Multiple Myeloma
5
2024
5
0.810
Why?
Maintenance Chemotherapy
4
2021
14
0.790
Why?
CD3 Complex
1
2022
65
0.780
Why?
Immunotherapy
5
2024
250
0.770
Why?
Injection Site Reaction
2
2021
3
0.760
Why?
Disease-Free Survival
15
2022
241
0.760
Why?
Health Status Disparities
1
2023
143
0.750
Why?
Disease Progression
15
2024
1159
0.720
Why?
Sulfides
2
2020
22
0.720
Why?
Acetates
2
2020
32
0.710
Why?
Quinolines
2
2020
42
0.710
Why?
Cyclopropanes
2
2020
49
0.710
Why?
Proteasome Inhibitors
10
2023
30
0.710
Why?
Immunoconjugates
2
2024
89
0.700
Why?
Spectrometry, Mass, Electrospray Ionization
1
2021
93
0.690
Why?
Transplantation Conditioning
5
2019
102
0.690
Why?
Amyloidosis
3
2016
63
0.690
Why?
Cytochrome P-450 CYP1A2 Inducers
1
2020
1
0.690
Why?
Risk Assessment
7
2025
2036
0.680
Why?
Models, Statistical
1
2022
307
0.670
Why?
Thromboembolism
1
2020
72
0.670
Why?
Neoplasm Staging
9
2025
485
0.660
Why?
Drug Administration Schedule
8
2021
299
0.650
Why?
Immunophenotyping
2
2018
193
0.630
Why?
Practice Patterns, Physicians'
2
2024
707
0.630
Why?
Consensus
8
2025
224
0.630
Why?
Karnofsky Performance Status
1
2019
12
0.630
Why?
Skin Neoplasms
2
2016
413
0.620
Why?
Induction Chemotherapy
7
2023
41
0.620
Why?
Translocation, Genetic
6
2025
68
0.620
Why?
Follow-Up Studies
16
2025
2442
0.610
Why?
Immunomodulation
1
2018
30
0.610
Why?
Gene Expression Profiling
8
2025
761
0.580
Why?
Dental Prophylaxis
1
2018
1
0.580
Why?
Kaplan-Meier Estimate
8
2021
416
0.570
Why?
Clinical Trials, Phase III as Topic
6
2025
41
0.570
Why?
Fluorodeoxyglucose F18
3
2017
95
0.560
Why?
Genomics
6
2025
357
0.550
Why?
Signaling Lymphocytic Activation Molecule Family
1
2017
5
0.550
Why?
Survival Analysis
7
2020
575
0.550
Why?
Central Nervous System Neoplasms
2
2016
39
0.550
Why?
Catheterization, Central Venous
1
2018
86
0.540
Why?
Lymphoma, B-Cell
3
2025
61
0.540
Why?
Dose-Response Relationship, Drug
6
2025
861
0.540
Why?
Bacteremia
1
2018
94
0.530
Why?
Cancer Survivors
1
2018
112
0.530
Why?
Infusions, Intravenous
4
2021
173
0.530
Why?
Blood Transfusion
1
2017
157
0.520
Why?
Ambulatory Care
1
2019
310
0.520
Why?
United States
12
2023
7700
0.520
Why?
Antineoplastic Agents, Alkylating
1
2016
34
0.520
Why?
Incidence
7
2024
1359
0.520
Why?
Cell Proliferation
2
2020
981
0.520
Why?
Oligonucleotide Array Sequence Analysis
1
2017
297
0.510
Why?
Disease Management
6
2021
234
0.510
Why?
Myeloproliferative Disorders
1
2016
15
0.510
Why?
Health Status
1
2019
433
0.510
Why?
Skin Diseases, Infectious
1
2016
12
0.510
Why?
Bone Marrow
7
2023
178
0.510
Why?
Plasmacytoma
3
2022
9
0.500
Why?
Molecular Targeted Therapy
4
2020
129
0.500
Why?
Boron Compounds
3
2024
20
0.460
Why?
Proportional Hazards Models
8
2023
724
0.460
Why?
Prospective Studies
13
2025
3248
0.460
Why?
Glycine
3
2024
49
0.450
Why?
Gene Expression Regulation, Neoplastic
7
2025
520
0.450
Why?
Biomarkers
7
2022
1379
0.440
Why?
Combined Modality Therapy
7
2021
365
0.440
Why?
Tumor Microenvironment
5
2023
152
0.440
Why?
Remission Induction
6
2025
146
0.440
Why?
Thrombocytopenia
2
2025
52
0.440
Why?
Hepatitis C
1
2016
151
0.430
Why?
Killer Cells, Natural
3
2020
216
0.430
Why?
Neoplasms
2
2018
1348
0.420
Why?
Serum Amyloid A Protein
1
2013
7
0.420
Why?
Young Adult
12
2025
4613
0.410
Why?
Leukemia
1
2013
62
0.410
Why?
Receptors, G-Protein-Coupled
2
2024
127
0.400
Why?
Standard of Care
2
2023
27
0.400
Why?
Clinical Trials, Phase II as Topic
4
2023
25
0.390
Why?
Neoplasms, Plasma Cell
2
2023
3
0.390
Why?
Soft Tissue Neoplasms
1
2012
31
0.380
Why?
Myelodysplastic Syndromes
1
2013
86
0.380
Why?
Hemophilia A
1
2011
57
0.380
Why?
Immunoglobulins, Intravenous
1
2011
35
0.370
Why?
Antibodies, Monoclonal, Murine-Derived
1
2011
58
0.370
Why?
Bone Neoplasms
1
2013
125
0.370
Why?
Frailty
2
2025
130
0.370
Why?
In Situ Hybridization, Fluorescence
5
2020
168
0.370
Why?
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
2
2021
84
0.360
Why?
Clinical Decision-Making
3
2025
159
0.360
Why?
Risk Factors
10
2024
5293
0.360
Why?
Cost-Benefit Analysis
2
2024
308
0.350
Why?
Benzodioxoles
1
2010
13
0.350
Why?
Purines
1
2010
42
0.350
Why?
Clinical Trials, Phase I as Topic
3
2023
15
0.350
Why?
Monoclonal Gammopathy of Undetermined Significance
3
2024
33
0.340
Why?
Lymphoma, T-Cell
2
2025
24
0.340
Why?
Cytogenetic Analysis
5
2022
25
0.340
Why?
Immunoglobulin Light-chain Amyloidosis
2
2021
6
0.340
Why?
Hematopoietic Stem Cell Mobilization
3
2022
14
0.340
Why?
Positron Emission Tomography Computed Tomography
3
2020
50
0.330
Why?
Magnetic Resonance Imaging
7
2018
2142
0.330
Why?
DNA Copy Number Variations
3
2024
69
0.330
Why?
Adolescent
9
2025
6151
0.320
Why?
Protein-Tyrosine Kinases
2
2025
125
0.320
Why?
Europe
2
2020
193
0.320
Why?
Stem Cell Transplantation
3
2023
78
0.320
Why?
Healthcare Disparities
2
2023
348
0.320
Why?
Benzoquinones
1
2009
14
0.320
Why?
Liver Neoplasms
1
2012
294
0.320
Why?
Lactams, Macrocyclic
1
2009
25
0.310
Why?
Randomized Controlled Trials as Topic
7
2024
729
0.300
Why?
Boronic Acids
3
2013
28
0.290
Why?
Pyrazines
3
2013
34
0.290
Why?
Neutropenia
3
2023
67
0.290
Why?
Chromosome Deletion
2
2020
42
0.280
Why?
Bone Marrow Cells
4
2022
237
0.280
Why?
T-Lymphocytes, Regulatory
2
2020
213
0.270
Why?
Databases, Factual
4
2020
850
0.270
Why?
Myeloablative Agonists
3
2015
13
0.260
Why?
Diarrhea
2
2024
76
0.260
Why?
Cross-Sectional Studies
2
2024
2532
0.250
Why?
Adrenal Cortex Hormones
2
2024
173
0.250
Why?
Antigens, CD19
1
2025
22
0.240
Why?
Immunity, Humoral
1
2025
40
0.240
Why?
Chemoradiotherapy
1
2025
65
0.240
Why?
Mutagenesis
1
2025
130
0.240
Why?
Receptors, Antigen, T-Cell
2
2024
287
0.230
Why?
Surveys and Questionnaires
2
2024
2641
0.220
Why?
Whole Genome Sequencing
4
2025
70
0.220
Why?
Chromatography, Liquid
2
2021
130
0.220
Why?
Mutation
4
2025
2571
0.220
Why?
Neoplasm Proteins
2
2018
283
0.220
Why?
Proteasome Endopeptidase Complex
2
2016
125
0.210
Why?
Models, Theoretical
1
2025
271
0.210
Why?
Rituximab
2
2015
83
0.210
Why?
CD47 Antigen
1
2023
3
0.210
Why?
Meta-Analysis as Topic
1
2023
78
0.210
Why?
Heterocyclic Compounds
1
2022
12
0.200
Why?
Gene Deletion
2
2024
303
0.200
Why?
Spain
2
2020
33
0.200
Why?
Gene Dosage
2
2021
64
0.200
Why?
Tumor Suppressor Protein p53
1
2025
303
0.200
Why?
Sex Factors
2
2023
969
0.200
Why?
Graft vs Host Disease
1
2023
110
0.200
Why?
Canada
2
2020
154
0.200
Why?
Cell Cycle Proteins
1
2025
396
0.200
Why?
Animals
10
2024
20570
0.190
Why?
Workflow
1
2022
68
0.190
Why?
Tomography, X-Ray Computed
3
2018
1584
0.190
Why?
Biological Therapy
1
2022
16
0.190
Why?
Artificial Intelligence
1
2024
163
0.190
Why?
Leukemia, Plasma Cell
1
2021
2
0.190
Why?
Software
1
2025
381
0.190
Why?
Cell Line, Tumor
5
2016
1451
0.190
Why?
Electrocardiography
1
2024
549
0.180
Why?
CD8-Positive T-Lymphocytes
2
2024
671
0.180
Why?
Nutritional Status
1
2022
98
0.180
Why?
Drug Administration Routes
1
2021
21
0.180
Why?
Time Factors
5
2020
3739
0.180
Why?
Population Surveillance
2
2020
203
0.180
Why?
Retreatment
2
2019
47
0.180
Why?
Immunoglobulin A
1
2021
97
0.180
Why?
Genetic Loci
1
2021
117
0.170
Why?
Administration, Cutaneous
1
2020
31
0.170
Why?
Leukemia, Myeloid, Acute
1
2023
189
0.170
Why?
Patient Dropouts
1
2020
49
0.170
Why?
Denmark
1
2020
17
0.170
Why?
Netherlands
1
2020
24
0.170
Why?
Medical Oncology
1
2021
66
0.170
Why?
Infusion Pumps
1
2020
7
0.170
Why?
Sweden
1
2020
56
0.170
Why?
Patient Satisfaction
2
2021
431
0.170
Why?
Disease Susceptibility
1
2020
166
0.170
Why?
Influenza, Human
1
2022
206
0.170
Why?
Hemoglobins
2
2018
135
0.170
Why?
Mass Spectrometry
1
2021
304
0.160
Why?
Drug Compounding
1
2020
75
0.160
Why?
Diagnostic Imaging
2
2020
261
0.160
Why?
Prednisone
1
2019
86
0.160
Why?
Thrombopoietin
1
2019
11
0.160
Why?
Immunoglobulin G
1
2021
462
0.160
Why?
Apoptosis
3
2023
1066
0.160
Why?
Paraproteinemias
1
2019
16
0.160
Why?
Cancer Care Facilities
1
2019
17
0.160
Why?
Diphenhydramine
1
2019
9
0.160
Why?
Premedication
1
2019
16
0.160
Why?
Outpatient Clinics, Hospital
1
2019
39
0.160
Why?
Transplantation, Haploidentical
1
2018
4
0.160
Why?
Risk
5
2021
373
0.160
Why?
Venous Thromboembolism
1
2020
147
0.160
Why?
Cystitis
1
2018
10
0.150
Why?
Receptors, KIR
1
2018
3
0.150
Why?
Stem Cells
1
2021
259
0.150
Why?
Ibuprofen
1
2018
18
0.150
Why?
Myeloid-Derived Suppressor Cells
1
2018
7
0.150
Why?
B-Lymphocytes, Regulatory
1
2018
5
0.150
Why?
Multimodal Imaging
1
2019
66
0.150
Why?
Thoracic Vertebrae
1
2018
33
0.150
Why?
Diabetes Mellitus
1
2024
536
0.150
Why?
Cell Count
1
2018
130
0.150
Why?
Antibody-Dependent Cell Cytotoxicity
1
2018
26
0.150
Why?
Cytogenetics
2
2016
9
0.150
Why?
Models, Biological
2
2020
1180
0.150
Why?
Back Pain
1
2018
50
0.150
Why?
Acetaminophen
1
2019
59
0.150
Why?
Patient Safety
1
2021
242
0.150
Why?
Precancerous Conditions
2
2016
70
0.150
Why?
Immunoglobulin Fc Fragments
1
2018
46
0.150
Why?
Periodontal Index
1
2018
4
0.150
Why?
Drugs, Investigational
1
2018
12
0.150
Why?
Pandemics
1
2023
661
0.140
Why?
Receptors, IgG
1
2018
37
0.140
Why?
Bone and Bones
2
2016
142
0.140
Why?
Antibiotic Prophylaxis
1
2018
54
0.140
Why?
Neoadjuvant Therapy
1
2018
78
0.140
Why?
Catheter-Related Infections
1
2018
42
0.140
Why?
Glucocorticoids
1
2019
188
0.140
Why?
Comorbidity
1
2020
1117
0.140
Why?
Lumbar Vertebrae
1
2018
142
0.140
Why?
Phagocytosis
1
2018
264
0.140
Why?
Chronic Disease
1
2020
748
0.130
Why?
Hemorrhage
1
2018
266
0.130
Why?
B-Lymphocytes
1
2020
569
0.130
Why?
Feasibility Studies
1
2019
562
0.130
Why?
Gene Expression
1
2020
836
0.130
Why?
Odds Ratio
1
2018
768
0.130
Why?
Cohort Studies
3
2019
2530
0.130
Why?
Zonula Occludens-1 Protein
1
2016
7
0.130
Why?
Leukemia, Lymphocytic, Chronic, B-Cell
1
2016
46
0.130
Why?
Janus Kinase 1
1
2016
11
0.130
Why?
Pneumonia
1
2019
286
0.130
Why?
Schnitzler Syndrome
1
2016
1
0.130
Why?
Scleromyxedema
1
2016
1
0.130
Why?
POEMS Syndrome
1
2016
2
0.130
Why?
Cryoglobulinemia
1
2016
3
0.130
Why?
Xanthomatosis
1
2016
8
0.130
Why?
Osteoclasts
2
2013
48
0.130
Why?
Radiopharmaceuticals
2
2017
186
0.130
Why?
Genetic Predisposition to Disease
1
2020
712
0.130
Why?
Phenotype
1
2020
1190
0.130
Why?
STAT3 Transcription Factor
1
2016
70
0.120
Why?
Biomarkers, Pharmacological
2
2012
6
0.120
Why?
ErbB Receptors
1
2016
114
0.120
Why?
Lymphoma, Follicular
1
2015
16
0.120
Why?
Bone Marrow Transplantation
1
2015
139
0.120
Why?
Immunoglobulin Heavy Chains
2
2025
46
0.120
Why?
Bone Remodeling
1
2015
25
0.120
Why?
Mice
5
2024
10800
0.120
Why?
Costs and Cost Analysis
1
2015
101
0.120
Why?
Genetic Markers
1
2015
126
0.110
Why?
Histone Deacetylase Inhibitors
1
2014
36
0.110
Why?
Medicare
1
2019
614
0.110
Why?
Renal Insufficiency
1
2014
67
0.110
Why?
Chromosomes, Human, Pair 17
1
2014
24
0.110
Why?
Antigens, CD34
1
2013
56
0.110
Why?
Unfolded Protein Response
2
2013
56
0.110
Why?
Cerebrospinal Fluid
1
2013
23
0.110
Why?
Administration, Metronomic
1
2013
2
0.110
Why?
Cell Separation
1
2013
147
0.110
Why?
Radiography
2
2012
533
0.110
Why?
Castleman Disease
1
2013
4
0.110
Why?
Transplantation, Homologous
3
2022
244
0.110
Why?
Nicotinamide Phosphoribosyltransferase
1
2013
5
0.100
Why?
Angiogenesis Inhibitors
1
2014
77
0.100
Why?
beta Catenin
1
2013
93
0.100
Why?
Osteolysis
1
2013
17
0.100
Why?
Bone Diseases
1
2013
22
0.100
Why?
Piperidines
3
2020
63
0.100
Why?
Signal Transduction
5
2016
3019
0.100
Why?
Cell Cycle
2
2013
392
0.100
Why?
Mice, SCID
4
2016
519
0.100
Why?
Myelolipoma
1
2012
1
0.100
Why?
Antiretroviral Therapy, Highly Active
1
2013
95
0.100
Why?
Genome, Human
2
2025
233
0.100
Why?
Receptors, Glucocorticoid
1
2012
27
0.100
Why?
Longitudinal Studies
3
2024
1247
0.100
Why?
Hemarthrosis
1
2011
3
0.100
Why?
Severity of Illness Index
2
2020
1540
0.100
Why?
Factor VIII
1
2011
32
0.100
Why?
Granulocyte Colony-Stimulating Factor
2
2022
41
0.090
Why?
Blood Coagulation Factors
1
2011
16
0.090
Why?
Pericardial Effusion
1
2011
21
0.090
Why?
Hydrazines
2
2022
10
0.090
Why?
Vaccination
2
2025
353
0.090
Why?
Epigenesis, Genetic
1
2015
382
0.090
Why?
Triazoles
2
2022
56
0.090
Why?
Acute Disease
1
2013
670
0.090
Why?
Cell Movement
1
2013
445
0.090
Why?
Autoantibodies
1
2011
182
0.090
Why?
Drug Evaluation, Preclinical
1
2011
97
0.090
Why?
Heart Failure
1
2018
899
0.090
Why?
Body Weight
2
2023
377
0.090
Why?
G1 Phase
1
2010
56
0.090
Why?
Multivariate Analysis
1
2013
928
0.090
Why?
S Phase
1
2010
78
0.090
Why?
Drug Therapy, Combination
1
2011
463
0.080
Why?
Multicenter Studies as Topic
2
2021
137
0.080
Why?
Pain
2
2023
406
0.080
Why?
Diet
2
2024
522
0.080
Why?
Cyclophosphamide
2
2021
79
0.080
Why?
Fatigue
2
2022
112
0.080
Why?
Metabolic Clearance Rate
2
2020
49
0.080
Why?
International Agencies
2
2019
7
0.080
Why?
Drug Screening Assays, Antitumor
1
2009
82
0.080
Why?
Cell Differentiation
4
2018
1346
0.080
Why?
Adenine
2
2020
50
0.080
Why?
Cytokines
1
2013
933
0.080
Why?
Pyrazoles
2
2020
78
0.070
Why?
Nausea
1
2009
112
0.070
Why?
Pyrimidines
2
2020
135
0.070
Why?
Vomiting
1
2009
138
0.070
Why?
CD4-Positive T-Lymphocytes
2
2025
641
0.070
Why?
Algorithms
2
2025
1003
0.070
Why?
Body Mass Index
2
2023
861
0.070
Why?
Doxorubicin
2
2021
99
0.070
Why?
Cisplatin
2
2021
139
0.070
Why?
Thymus Hyperplasia
1
2006
2
0.070
Why?
Chemotherapy, Adjuvant
1
2006
85
0.060
Why?
HIV Infections
1
2013
962
0.060
Why?
Trisomy
1
2025
21
0.060
Why?
Brain
1
2013
1549
0.060
Why?
Fatal Outcome
1
2025
122
0.060
Why?
Lentivirus
1
2025
66
0.060
Why?
Genes, Tumor Suppressor
1
2024
72
0.060
Why?
Sweetening Agents
1
2024
21
0.050
Why?
Protein Interaction Maps
1
2023
35
0.050
Why?
Cell Transformation, Neoplastic
1
2025
206
0.050
Why?
Ki-67 Antigen
1
2023
37
0.050
Why?
Diet, Vegetarian
1
2022
3
0.050
Why?
Nutrition Surveys
1
2024
142
0.050
Why?
Germinal Center
1
2023
40
0.050
Why?
Proteinuria
1
2023
41
0.050
Why?
Butyrates
1
2022
16
0.050
Why?
Immunoglobulins
1
2023
77
0.050
Why?
Myeloid Differentiation Factor 88
1
2023
204
0.050
Why?
Homeodomain Proteins
1
2024
266
0.050
Why?
Drug Combinations
1
2022
152
0.050
Why?
Single-Chain Antibodies
1
2021
7
0.050
Why?
Diterpenes
1
2021
21
0.050
Why?
Filgrastim
1
2021
7
0.050
Why?
Etoposide
1
2021
33
0.050
Why?
Taiwan
1
2021
10
0.050
Why?
RNA Interference
2
2016
618
0.050
Why?
Neurotoxicity Syndromes
1
2021
21
0.050
Why?
Japan
1
2021
59
0.040
Why?
Immunoglobulin kappa-Chains
1
2020
9
0.040
Why?
Immunoglobulin lambda-Chains
1
2020
10
0.040
Why?
Immunohistochemistry
1
2023
888
0.040
Why?
Up-Regulation
2
2013
375
0.040
Why?
Lymphoproliferative Disorders
1
2021
39
0.040
Why?
Liver Function Tests
1
2020
39
0.040
Why?
Cost Savings
1
2021
54
0.040
Why?
Lymphoma, Non-Hodgkin
1
2021
52
0.040
Why?
Case-Control Studies
1
2024
1108
0.040
Why?
Neoplastic Cells, Circulating
1
2020
15
0.040
Why?
Benchmarking
1
2021
132
0.040
Why?
Injections, Intravenous
1
2020
156
0.040
Why?
Molecular Diagnostic Techniques
1
2020
32
0.040
Why?
Antibodies, Neutralizing
1
2022
206
0.040
Why?
Chromosomes, Human
1
2020
53
0.040
Why?
Kidney
1
2023
444
0.040
Why?
Republic of Korea
1
2021
163
0.040
Why?
ROC Curve
1
2020
277
0.040
Why?
Reference Values
1
2020
335
0.040
Why?
Prevalence
1
2024
1346
0.040
Why?
Stevens-Johnson Syndrome
1
2019
8
0.040
Why?
Delivery of Health Care
1
2023
428
0.040
Why?
High-Throughput Nucleotide Sequencing
1
2021
288
0.040
Why?
Jehovah's Witnesses
1
2019
18
0.040
Why?
Pain Measurement
1
2020
339
0.040
Why?
Maximum Tolerated Dose
1
2019
40
0.040
Why?
Patient Acceptance of Health Care
1
2023
476
0.040
Why?
Global Health
1
2020
182
0.040
Why?
Basophils
1
2018
14
0.040
Why?
Health Care Costs
1
2021
210
0.040
Why?
Granzymes
1
2018
21
0.040
Why?
Antigens, Differentiation, T-Lymphocyte
1
2018
109
0.040
Why?
Drug Approval
1
2018
26
0.040
Why?
Myocarditis
1
2019
67
0.040
Why?
Autografts
1
2017
9
0.040
Why?
Hematology
1
2017
12
0.040
Why?
Allografts
1
2017
46
0.040
Why?
Education
1
2017
69
0.030
Why?
Breast Neoplasms
1
2006
1189
0.030
Why?
Polymorphism, Genetic
1
2018
189
0.030
Why?
RNA, Small Interfering
2
2013
898
0.030
Why?
Peripheral Nervous System Diseases
1
2016
28
0.030
Why?
Erlotinib Hydrochloride
1
2016
20
0.030
Why?
Atrial Fibrillation
1
2024
833
0.030
Why?
Radiotherapy
1
2016
64
0.030
Why?
Research Design
1
2019
572
0.030
Why?
Genetic Testing
1
2016
131
0.030
Why?
Cysteine Endopeptidases
1
2016
94
0.030
Why?
Reproducibility of Results
1
2020
1637
0.030
Why?
Cause of Death
1
2016
220
0.030
Why?
Child
1
2025
4431
0.030
Why?
Xenograft Model Antitumor Assays
1
2016
189
0.030
Why?
Neoplasm Grading
1
2015
87
0.030
Why?
Societies, Medical
1
2017
363
0.030
Why?
Hospitalization
1
2022
1338
0.030
Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2016
544
0.030
Why?
Blotting, Western
1
2016
610
0.030
Why?
Survivors
1
2015
169
0.030
Why?
Karyotype
1
2014
18
0.030
Why?
Interspersed Repetitive Sequences
1
2014
13
0.030
Why?
Low Density Lipoprotein Receptor-Related Protein-1
1
2013
2
0.030
Why?
Low Density Lipoprotein Receptor-Related Protein-6
1
2013
3
0.030
Why?
Syndecan-1
1
2013
9
0.030
Why?
Regulatory Factor X Transcription Factors
1
2013
15
0.030
Why?
X-Box Binding Protein 1
1
2013
13
0.030
Why?
Receptors, LDL
1
2013
34
0.030
Why?
Inhibitor of Apoptosis Proteins
1
2013
39
0.030
Why?
Neoplasm Transplantation
1
2013
165
0.030
Why?
Chemokine CXCL12
1
2013
17
0.030
Why?
Nicotinamide Mononucleotide
1
2013
2
0.030
Why?
Acrylamides
1
2013
15
0.030
Why?
Enzyme Induction
1
2013
45
0.030
Why?
Receptors, CXCR4
1
2013
36
0.030
Why?
Wnt Proteins
1
2013
98
0.030
Why?
Poly(ADP-ribose) Polymerases
1
2013
32
0.030
Why?
Niacinamide
1
2013
33
0.030
Why?
Transplantation, Heterologous
1
2013
229
0.030
Why?
Poly (ADP-Ribose) Polymerase-1
1
2013
18
0.030
Why?
Coculture Techniques
1
2013
97
0.030
Why?
Sirtuin 1
1
2013
27
0.030
Why?
Amides
1
2013
56
0.030
Why?
CD4 Lymphocyte Count
1
2013
93
0.030
Why?
Nitriles
1
2013
69
0.030
Why?
Wnt Signaling Pathway
1
2013
81
0.030
Why?
NAD
1
2013
53
0.020
Why?
Age Factors
1
2016
1553
0.020
Why?
Endoplasmic Reticulum
1
2013
173
0.020
Why?
Gene Knockdown Techniques
1
2013
201
0.020
Why?
Rabbits
1
2013
332
0.020
Why?
Tumor Suppressor Proteins
1
2013
198
0.020
Why?
Tumor Cells, Cultured
1
2013
454
0.020
Why?
Viral Load
1
2013
229
0.020
Why?
Cell Survival
1
2013
573
0.020
Why?
Genes, Neoplasm
1
2011
24
0.020
Why?
Repressor Proteins
1
2013
346
0.020
Why?
Pharmacogenetics
1
2011
27
0.020
Why?
Enzyme Inhibitors
1
2013
373
0.020
Why?
NF-kappa B
1
2013
469
0.020
Why?
Mice, Transgenic
1
2013
1271
0.020
Why?
Cells, Cultured
1
2013
2154
0.020
Why?
Cell Line
1
2013
2038
0.020
Why?
RNA-Binding Proteins
1
2011
432
0.020
Why?
DNA-Binding Proteins
1
2013
1183
0.020
Why?
Transcription Factors
1
2013
1506
0.020
Why?
Diagnosis, Differential
1
2006
963
0.010
Why?
Usmani's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (509)
Explore
_
Co-Authors (2)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_